CClinicalTrials.gg
CompletedNCT00446693Updated Nov 19, 2009

Clinical Investigation to Evaluate Safety and Performance of the EndoFast Reliant™ System in Vaginal Wall Reinforcement

An interventional study of EndoFast Reliant™ system for Pelvic Organ Prolapse repair in Pelvic Organ Prolapse, sponsored by Endogun Medical Systems Ltd.. Completed at 3 sites in 2 countries. Open to female participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2009-11-19.

Sponsored by Endogun Medical Systems Ltd. · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
40 Years to 80 Years
Sex
Female
01

Study summary

The purpose of this study is to clinically assess the safety and performance of the EndoFast Reliant™ system as a less invasive treatment for Pelvic Organ Prolapse.

Read the detailed description

Background:

Pelvic Organ Prolapse represents a significant problem worldwide and may have a significant negative impact on a woman's quality of life. The uterus, rectum and the bladder are held in their normal positions just above the inner end of the vagina by a "hammock" made up of supportive muscles and ligaments. Wear and tear on these supportive structures in the pelvis can allow the uterus, the bladder, the bowels, the vaginal vault or the rectum to sag through the muscle and ligament layers. When this occurs, the rectum, uterus, bowels or bladder can create a bulge into the vagina. In severe cases, it is possible for the sagging rectum, uterus, bowels or bladder to work its way down far enough that the bulge can appear at the vagina's opening or even protrude from the opening. Pelvic Organ Prolapse causes significant discomfort to the patients being associated with urinary incontinence, voiding difficulty culminating with urinary retention, constipation, pain during sexual intercourse, local discomfort, etc.

Treatment Options When symptoms occur, many patients initially opt for conservative treatment. Pelvic exercises and vaginal support are the current mainstays of non surgical management. In addition, patients who are poor surgical candidates or are strongly disinclined to surgery can be offered vaginal support (pessaries) for symptom relief. Topical estrogen is an important adjunct in the conservative management of patients with Pelvic Organ Prolapse. However, the primary management strategy for severe Pelvic Organ Prolapse is surgical. The exact treatment choice will depend on the severity of the prolapse and whether there are any related pelvic floor defects.

Endogun Medical Systems Ltd. has developed an innovative, minimally-invasive system for repair of Pelvic Floor Prolapse. The EndoFast Reliant™ system is a new concept of reinforcing the vaginal wall with a proprietary system comprised of a mesh and soft tissue fasteners in a minimally-invasive way. The fasteners can be deployed easily and swiftly in narrow spaces into soft tissue and can support substantially more weight than needed for Pelvic Organ Prolapse repair. Following many pre-clinical tests, the EndoFast Reliant™ system is now available for clinical evaluation.

The objective of this study is to evaluate the safety and performance of the EndoFast Reliant™ system for treatment of Pelvic Organ Prolapse.

In particular:

  • The study's primary goal is to clinically assess the safety of the EndoFast Reliant™ as a minimally-invasive procedure for vaginal wall reinforcement.
  • The study's secondary goal is to clinically evaluate the performance of the EndoFast Reliant™ system as a minimally-invasive procedure for vaginal wall reinforcement by evaluating the improvement in Pelvic Organ Prolapse using the POPQ grading system.

Study Procedures and Follow up:

Pre-treatment tests and inspection will be performed within 4 months prior to surgery.

Approximately two weeks, three months and six months after the surgery the patient will be invited for physician examination and laboratory tests.

Additional Study Measures:

In addition to the endpoint parameters, the following study measures will be collected:

  • Symptoms relief and Quality of Life (QOL) considerations.
  • Sexual Function considerations, as documented using the Female Sexual Function (FSFI) questionnaire;
  • Assessment of the physician's satisfaction.
02

Conditions studied

  • Pelvic Organ Prolapse
03

In context

Prolapse

676 studies on the registry are indexed under Prolapse; 79 are open to participants now.

This study's enrollment of 20 is below the median of 74 across 435 interventional studies indexed under Prolapse.

Browse Prolapse studies →

Lead sponsor

This is the only study on the registry with Endogun Medical Systems Ltd. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Female aged between 40-80 years (inclusive) who is not pregnant or planning to have further births.
  • Subject suffers from Pelvic Organ Prolapse confirmed by vaginal inspection.
  • Patient under reliable form of contraceptive measure or menopausal.
  • Subject able to comprehend procedure and has signed Informed Consent Form for participation in this study.
  • Subject able to complete the applicable questionnaires.

Exclusion criteria

Exclusion Criteria:

  • Planned to undergo hysterectomy.
  • Uterine prolapse equal to or greater than 3rd degree.
  • Documented Stress Urinary Incontinence on physical examination with full bladder or during complete urodynamic assessment with and without prolapse reduction.
  • Any chronic active and uncontrolled disease.
  • Vaginal bleeding disorders.
  • Needing emergency surgery.
  • Any acute disease.
  • Blood clotting disorders and/or anticoagulant treatment.
  • Known cognitive or psychiatric disorder.
  • High operative risk.
  • Any ongoing malignant disease.
  • Concurrent participation in any other clinical trial
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    I

    Use of EndoFast Reliant System

    Device: EndoFast Reliant™ system for Pelvic Organ Prolapse repair

Interventions

  • DeviceEndoFast Reliant™ system for Pelvic Organ Prolapse repair

    The EndoFast Reliant™ system is a new concept of reinforcing the vaginal wall with proprietary mesh and soft-tissue Fasteners in a minimally-invasive procedure.

06

What researchers measure

Primary outcomes

  1. Safety is defined as paucity of major device-related complications.

    Time frame: 12 months

Secondary outcomes

  1. Performance as defined by relative improvement in Pelvic Organ Prolapse staging (as reported post operatively versus preoperatively) using the POPQ grading system.

    Time frame: 12 months

07

Study locations

3 sites
  • CHU de Caen
    Caen, 14033, France
  • Hôpital Jeanne de Flandre - CHRU Gynécologie obstétrique
    Lille, 56037, France
  • Sheba Medical Center
    Ramat Gan, 52621, Israel
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 19, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00446693
Lead sponsor
Endogun Medical Systems Ltd.
First posted
Mar 13, 2007
Start date
Feb 2007
Primary completion
Jun 2008
Completion
Jun 2009
Last update
Nov 19, 2009

Study contacts

Peter Von Theobald, Prof.
principal investigator · Professeur d'Université-Praticien Hospitalier, gynécologie
Michel Cosson, Prof.
principal investigator · Hôpital Jeanne de Flandre - CHRU Gynécologie obstétrique
Genadi Bitman, MD
principal investigator · Sheba Medical Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion